Cost effectiveness of cancer drugs: comparative analysis of the United States and England

The Lancet

5 November 2020 - England's National Institute for Health and Care Excellence and the US’ Institute for Clinical and Economic Review both conduct cost-effectiveness evaluations for new cancer drugs to help payers make drug coverage decisions. 

However, NICE and ICER assessments have been noted to reach different conclusions. 

This study aimed to better understand the degree to which their recommendations diverge and what drives these apparent differences.

Read The Lancet article

Michael Wonder

Posted by:

Michael Wonder